ADARx Pharmaceuticals, Inc. today announced that Zhen Li, PhD, Co-Founder, President and CEO, will host one-on-one investor meetings at the 44th Annual Cowen Healthcare Conference on Monday, March 4, 2024 in Boston, Massachusetts.
SAN DIEGO--(BUSINESS WIRE)-- ADARx Pharmaceuticals Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will host one-on-one investor meetings at the 44th Annual Cowen Healthcare Conference on Monday, March 4, 2024 in Boston, Massachusetts.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA. ADARx has a growing pipeline of RNA therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiovascular, complement-mediated and central nervous system diseases. Follow ADARx on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221546347/en/
Source: ADARx Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240221546347/en
